Vladimir Tolmachev Selected Research

Chelating Agents

3/2020	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
1/2020	Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties.
11/2019	Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.
7/2019	Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6.
1/2019	Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.
1/2019	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.
8/2018	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules.
1/2016	Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
8/2012	Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
3/2012	Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vladimir Tolmachev Research Topics

Disease

168	Neoplasms (Cancer) 05/2022 - 01/2002
26	Prostatic Neoplasms (Prostate Cancer) 05/2022 - 04/2011
25	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2004
16	Neoplasm Metastasis (Metastasis) 05/2022 - 11/2004
14	Carcinoma (Carcinomatosis) 05/2020 - 11/2004
6	Ovarian Neoplasms (Ovarian Cancer) 05/2022 - 06/2005
6	Squamous Cell Carcinoma of Head and Neck 12/2019 - 11/2004
5	Glioma (Gliomas) 01/2018 - 05/2003
5	Glioblastoma (Glioblastoma Multiforme) 01/2018 - 08/2003
5	Colorectal Neoplasms (Colorectal Cancer) 01/2014 - 10/2005
5	Neoplasm Micrometastasis 09/2009 - 02/2002
3	Renal Cell Carcinoma (Grawitz Tumor) 10/2019 - 02/2015
2	Lymphoma (Lymphomas) 06/2022 - 05/2020
2	Disease Progression 01/2021 - 06/2019
2	Adenocarcinoma 02/2020 - 05/2012
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2016 - 01/2011
1	Osteosarcoma (Osteogenic Sarcoma) 05/2022
1	Triple Negative Breast Neoplasms 10/2020
1	Pancreatic Neoplasms (Pancreatic Cancer) 06/2020
1	Hypoxia (Hypoxemia) 12/2019

Drug/Important Bio-Agent (IBA)

68	Radioisotopes (Radionuclides)IBA 05/2022 - 02/2002
35	ErbB Receptors (EGF Receptor)IBA 01/2022 - 08/2004
25	Proteins (Proteins, Gene)FDA Link 11/2021 - 02/2004
25	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 10/2020 - 02/2007
18	Monoclonal AntibodiesIBA 01/2022 - 11/2004
17	Trastuzumab (Herceptin)FDA Link 01/2022 - 06/2005
16	Bombesin Receptors (Bombesin Receptor)IBA 11/2021 - 01/2013
16	Chelating AgentsIBA 03/2020 - 11/2006
13	human ERBB2 proteinIBA 01/2022 - 06/2005
13	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 11/2021 - 05/2011
12	AntigensIBA 07/2020 - 10/2005
11	Epidermal Growth Factor (EGF)IBA 01/2021 - 05/2003
10	Pharmaceutical PreparationsIBA 02/2022 - 10/2007
10	1- (1,3- carboxypropyl)- 4,7- carboxymethyl- 1,4,7- triazacyclononaneIBA 12/2020 - 03/2012
8	Designed Ankyrin Repeat ProteinsIBA 05/2022 - 01/2018
8	AntibodiesIBA 06/2020 - 08/2003
7	BombesinIBA 01/2020 - 01/2013
7	Pentetic Acid (DTPA)FDA LinkGeneric 12/2019 - 08/2003
7	Cys-ZHER2-342 affibodyIBA 01/2018 - 02/2007
6	Epithelial Cell Adhesion MoleculeIBA 05/2022 - 02/2020
6	AlbuminsIBA 02/2022 - 01/2018
6	Peptides (Polypeptides)IBA 10/2020 - 01/2002
6	ABY-025IBA 03/2020 - 04/2010
6	AndrogensIBA 07/2014 - 04/2011
5	Indium-111IBA 07/2021 - 04/2007
5	Tyrosine Kinase InhibitorsIBA 01/2021 - 11/2014
5	LigandsIBA 06/2020 - 04/2006
4	Immunoconjugates (Immunoconjugate)IBA 05/2022 - 11/2006
3	seribantumabIBA 09/2021 - 01/2018
3	Carbonic Anhydrase IXIBA 12/2019 - 11/2016
3	Hormones (Hormone)IBA 01/2019 - 04/2011
3	Cetuximab (Erbitux)FDA Link 01/2019 - 01/2011
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 07/2010
3	Peptide Nucleic AcidsIBA 01/2018 - 01/2016
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2017 - 03/2009
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2016 - 01/2007
3	Cysteine (L-Cysteine)FDA Link 04/2015 - 03/2007
2	Glucose (Dextrose)FDA LinkGeneric 06/2022 - 02/2016
2	EpitopesIBA 11/2021 - 05/2012
2	Aligeron (AS 2)IBA 01/2021 - 06/2010
2	68Ga-ABY-025IBA 03/2020 - 01/2016
2	EnzymesIBA 01/2020 - 11/2016
2	G250 monoclonal antibodyIBA 12/2019 - 02/2015
2	CobaltIBA 11/2019 - 01/2017
2	Immunoglobulin FragmentsIBA 10/2019 - 02/2016
2	Immunoglobulins (Immunoglobulin)IBA 01/2018 - 01/2016
2	pertuzumabIBA 01/2018 - 01/2007
2	Technetium (Technetium 99m)IBA 01/2018 - 03/2006
2	CD44v6 antigenIBA 02/2016 - 01/2010
2	Oncogene Proteins (Oncogene Protein)IBA 10/2015 - 06/2006
2	IndiumIBA 06/2014 - 11/2007
2	IodineIBA 06/2014 - 03/2006
2	IsotopesIBA 07/2013 - 11/2004
2	RadiopharmaceuticalsIBA 03/2011 - 03/2007
2	DABIIBA 01/2010 - 11/2004
2	dodecaborateIBA 01/2010 - 11/2004
2	benzyl-DTPAIBA 09/2007 - 08/2003
2	N- (2- amino- 3- (para- isothiocyanatophenyl)propyl)cyclohexane- 1,2- diamine- N,N,N',N',N'- pentaacetic acidIBA 03/2007 - 11/2006
2	Benzoates (Benzoate)IBA 07/2006 - 11/2004
1	Alkaline PhosphataseIBA 05/2022
1	OsteopontinIBA 05/2022
1	ExotoxinsIBA 05/2022
1	Gallium-66IBA 11/2021
1	glycylhistidineIBA 01/2021
1	Copper-64IBA 12/2020
1	Cobalt-55IBA 12/2020
1	Human Serum Albumin FDA LinkGeneric 10/2020
1	Blood Proteins (Serum Proteins)IBA 01/2020
1	phosphoramidonIBA 12/2019
1	pimonidazoleIBA 12/2019
1	GlutamatesIBA 08/2019

Therapy/Procedure

86	Therapeutics 05/2022 - 02/2002
7	Radioimmunotherapy 08/2015 - 10/2005
7	Gamma Cameras (Gamma Camera) 11/2014 - 04/2006
3	Radiotherapy 12/2019 - 01/2007
2	Investigational Therapies (Experimental Therapy) 12/2020 - 01/2007
2	Precision Medicine 07/2019 - 10/2015
2	Immunotherapy 01/2018 - 01/2014
2	Intravenous Injections 05/2014 - 05/2012
1	Cyclotrons 11/2021